ADMA Biologics (ADMA) stock is back in focus after multiple law firms filed securities fraud class action lawsuits alleging channel stuffing, undisclosed related party transactions, and misleading statements about internal controls.

At a recent share price of $8.72, ADMA Biologics has seen short term momentum pick up, with a 1 month share price return of 6.99% and 7 day share price return of 4.93%, even though the year to date share price return is down 51.23% and the 1 year total shareholder return is down 52.61%, while the 3 year and 5 year total shareholder returns remain very strong.

If this legal setback has you reassessing risk in your portfolio, it could be a useful moment to scan for other healthcare stocks using 39 healthcare AI stocks

So, with ADMA Biologics trading at $8.72 and sitting far below some analyst valuation measures despite very strong multi year total returns, is the current legal overhang creating a potential opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 50.5% Undervalued

Compared to the last close at $8.72, the most followed fair value narrative for ADMA Biologics points to a much higher value, which hinges on execution across manufacturing, products, and funding.

Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion and higher net income starting in early 2026 and beyond.

Curious what kind of revenue ramp, margin profile, and future earnings multiple are baked into that fair value for ADMA Biologics? The narrative rests on compounding growth assumptions, a step change in profitability, and a specific view on how the market could price those earnings a few years out. The full breakdown lays out the math behind the $17.60 fair value and how it compares with where the stock trades today.

Result: Fair Value of $17.60 (UNDERVALUED)

However, the ADMA Biologics story also carries clear risks, including heavy reliance on ASCENIV and BIVIGAM, as well as potential pressure from larger plasma competitors and shifting reimbursement.

Next Steps

If the mix of legal risk and potential upside around ADMA Biologics feels finely balanced, it may be useful to move quickly and review the underlying data yourself before sentiment shifts again. To see what investors are optimistic about, start by assessing the 3 key rewards.

Looking for more investment ideas beyond ADMA Biologics?

Once you have weighed the legal and valuation picture for ADMA Biologics, do not stop there, other focused stock ideas could sharpen your overall portfolio.

• Target potential high upside by scanning 22 elite penny stocks with strong financials that already show strong financial foundations instead of just speculative stories.
• Strengthen your core holdings by reviewing solid balance sheet and fundamentals stocks screener (48 results) that pair resilient finances with consistent fundamentals.
• Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems that combine quality metrics with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.